Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2002

View Archived Issues

NNC-45-0781, a promising candidate for postmenopausal osteoporosis

Antitumor effects demonstrated for rapamycin at immunosuppressive doses

Influenza vaccination reduces risk of brain infarction according to French researchers

Seattle Genetics and Genencor jointly develop ADEPT products including SGN-17/19

FDA approves BioPort anthrax vaccine license supplements

Preclinical evidence for efficacy of celecoxib in inflammatory bowel disease

Forbes Medi-Tech initiates phase I trial of cholesterol-lowering pharmaceutical

AltaRex offers further analysis of OvaRex results

Corixa reports progress in 2001

Malarex: a natural alternative in the fight against malaria

Chiron and Global Alliance for TB Drug Development collaborate on PA-824

Gleevec approved for gastrointestinal stromal tumors

National Institute on Aging studies genetic traits in Sardinians

Oxigene highlights product developments in fourth quarter 2001

First approval obtained for antihypertensive combination developed in Spain

Clinical testing of candidate HIV vaccine developed at GSK commences in U.S.

Tricyclic compounds that inhibit MRP-1 are useful as oncolytics

Radiolabeled nucleoside compounds for use as cancer imaging and therapeutic agents

Corixa designs isoleucine-containing peptide prodrugs of antitumor agents

Quinazoline derivatives that act as NPY antagonists for eating disorders, etc.

Preparation and use of pipecolic acid derivatives with MMP-inhibitory activity

Aromatic alphavbeta3 and/or alphavbeta5 integrin receptor antagonists disclosed by Pharmacia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.